Acurx pharmaceuticals, inc. announces pricing of $4.0 million registered direct offering

Staten island, n.y. , may 16, 2023 /prnewswire/ -- acurx pharmaceuticals, inc. (nasdaq: acxp) ("acurx" or the "company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 1,333,333 shares of its common stock (or pre-funded warrants in lieu thereof) at a combined effective purchase price of $3.00 per share (or pre-funded warrant) in a registered direct offering.
ACXP Ratings Summary
ACXP Quant Ranking